Since the frequency of the mutations in ESR1 is higher in metastatic BC than in primary tumors, the assessment of this gene’s variants in plasma cfDNA might help in selecting treatment strategies, e.g., the administration of Fulvestrant in patients with a mutation in ESR1 was found to improve tumor-free survival [162]. The gene discussed is ESR1; the disease is breast cancer.